Cerus (CERS) Appoints Dean Gregory to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors
July 2, 2024 4:00 PM EDTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year.
We are very pleased to welcome Mr. Gregory to Cerus Board of Directors, said Daniel Swisher,... More
